Search

Your search keyword '"Ahluwalia, Jasmina"' showing total 26 results
Start Over Author "Ahluwalia, Jasmina" Publisher lippincott williams & wilkins
26 results on '"Ahluwalia, Jasmina"'

16. HbSD-Punjab.

Author

Oberoi, Sapna, Das, Reena, Trehan, Amita, Ahluwalia, Jasmina, Bansal, Deepak, Malhotra, Pankaj, and Marwaha, Ram K.

Published
2014
Full Text
View/download PDF

21. Reply.

Author

Rao, Sandeep and Ahluwalia, Jasmina

Published
2015

23. Thrombophilic risk factors are uncommon in young patients with retinal vein occlusion.

Author

Ahluwalia J, Rao S, Varma S, Gupta A, Bose S, Masih J, Das R, Kumar N, Naseem S, Sharma P, Sachdeva MU, and Varma N

Subjects
Adolescent, Adult, Antibodies, Antiphospholipid blood, Biomarkers blood, Child, DNA Mutational Analysis, Factor V genetics, Female, Humans, Male, Middle Aged, Polymerase Chain Reaction, Protein C metabolism, Protein S metabolism, Retinal Vein Occlusion blood, Risk Factors, Thrombophilia blood, Retinal Vein Occlusion etiology, Thrombophilia complications
Abstract

Purpose: To study the thrombotic factors, namely deficiencies of plasma proteins C, S, and antithrombin, factor V Leiden mutation, and positivity for antiphospholipid antibodies in young patients with retinal vein occlusion., Methods: The thrombophilia parameters listed above were analyzed from the laboratory records of 50 patients with the clinical diagnosis of retinal vein occlusion, aged less than 50 years., Results: A single prothrombotic factor was seen in 2 (4%) cases. The highest positivity was for the antiphospholipid antibodies (lupus anticoagulant in 6%, anticardiolipin antibodies in 2%, and anti-β 2 glycoprotein 1 in 10% cases). Other than one case where antiphospholipid syndrome was confirmed, these were transient. One patient had antithrombin deficiency. Protein C and protein S deficiency and factor V Leiden mutation were not seen in this group., Conclusion: Our data suggest that these thrombophilia risk factors are not commonly associated with retinal vein occlusion, and there is a need for studies on other factors that contribute to the development of this condition.

Published
2015
Full Text
View/download PDF

25. HbSD-Punjab: clinical and hematological profile of a rare hemoglobinopathy.

Author

Oberoi S, Das R, Trehan A, Ahluwalia J, Bansal D, Malhotra P, and Marwaha RK

Subjects
Acute Chest Syndrome blood, Acute Chest Syndrome drug therapy, Anemia blood, Anemia drug therapy, Antisickling Agents, Child, Child, Preschool, Chromatography, High Pressure Liquid, Female, Fetal Hemoglobin analysis, Hemoglobin, Sickle analysis, Hemoglobinopathies blood, Hemoglobinopathies drug therapy, Humans, Hydroxyurea therapeutic use, India, Infant, Male, Pain blood, Pain diagnosis, Pain drug therapy, Retrospective Studies, Vascular Diseases blood, Vascular Diseases drug therapy, Acute Chest Syndrome diagnosis, Anemia diagnosis, Hemoglobinopathies diagnosis, Hemoglobins, Abnormal analysis, Vascular Diseases diagnosis
Abstract

Purpose: Compound heterozygous HbSD-Punjab is an uncommon hemoglobinopathy encountered in Indians. Limited literature is available about its clinical course. The aim of this study was to describe the clinical and hematological profile of HbSD-Punjab patients from North India., Materials and Methods: HbSD-Punjab patients diagnosed in the hematology clinics between year 2000 and 2010 were reviewed retrospectively. The diagnosis was established using high-performance liquid chromatography, molecular analysis, and family screening. Clinical details, laboratory parameters, and therapy details were recorded from case records., Results: Ten patients were identified. Median age at onset of symptoms was 3.5 years (interquartile range [IQR], 1.9 to 7.2). Clinical presentation included: anemia in 3, painful vaso-occlusive crisis in 2, acute chest syndrome in 2, and 3 were diagnosed incidentally. All had moderate to severe anemia (mean hemoglobin [Hb]: 6.8 ± 1.2 g/dL). Eight required red cell transfusions (median: 3 [IQR, 2 to 8]). On high-performance liquid chromatography, median HbF, HbD, and HbS were 12.1% (IQR, 9 to 18.3), 39.7% (IQR, 35 to 42), and 38.5% (IQR, 29 to 43). Five patients received hydroxyurea (HDU), median dose: 20 mg/kg/d (IQR, 18 to 23) with median duration of 7 months (IQR; 6, 45). Increment in Hb and reduction in painful crisis was observed in response to HDU., Conclusions: HbSD-Punjab has a heterogeneous clinical presentation. Anemia and sickle crises are quite common. HDU may be considered for those presenting with severe phenotype.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results